Claris Lifesciences trades in red despite receiving ANDA approvals for Ondensetron Injection in US

25 Feb 2013 Evaluate

Claris Lifesciences is currently trading at Rs 187.00, down by 7.15 points or 3.68% from its previous closing of Rs 194.15 on the BSE.

The scrip opened at Rs 194.00 and has touched a high and low of Rs 199.00 and Rs 184.60 respectively. So far 108175 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 292.20 on 05-Dec-2012 and a 52 week low of Rs 135.00 on 29-Mar-2012.

Last one week high and low of the scrip stood at Rs 206.65 and Rs 189.00 respectively. The current market cap of the company is Rs 1206.16 crore.

The promoters holding in the company stood at 62.06% while Institutions and Non-Institutions held 21.65% and 16.29% respectively.

Claris Lifesciences (Claris) has received two abbreviated new drug application (ANDA) approvals for Ondensetron Injection in the United States of America (US). Ondansetron Injection is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and for prevention of postoperative nausea and/or vomiting.

The company plans to launch Ondensetron in two variants of 2 mg/ml in 2 ml single dosage vials and 20 ml multi dosage vials. The total addressable market size of the product is estimated at $49 million in the US.

Claris Lifesciences has recently received the long awaited USFDA approval for its manufacturing facility. The company now has nine ANDAs approved in its name across four molecules. The company has a total filing of 30 ANDAs across 20 products.

Peers
Company Name CMP
Redington 268.15
Adani Enterprises 2203.00
Amrapali Industries 14.05
Rashi Peripheral 347.70
PDS 374.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×